EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update

2020/01/22 by Josef S Smolen, Robert Landewé, Robert B M Landewé +62 · 31 citations
Medicine · Immunology and Microbiology · #Rheumatoid Arthritis Research and Therapies #Biosimilars and Bioanalytical Methods #Systemic Lupus Erythematosus Research

paper · pdf · doi:10.1136/annrheumdis-2019-216655

Citations

• 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Cited by

• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
• 2026 EULAR updated standardised operating procedures and methods for the development of recommendations or points to consider for the diagnosis and management of people with rheumatic and musculoskeletal diseases
• Interactions between NSAIDs, opioids and the gut microbiota - Future perspectives in the management of inflammation and pain
• HandScan criteria versus ACR/EULAR Boolean remission as treatment target in early rheumatoid arthritis: results of a randomized controlled trial
• Understanding exosomes: Part 2—Emerging leaders in regenerative medicine
• Conventional disease-modifying agents in rheumatoid arthritis – a review of their current use and role in treatment algorithms
• COVID-19 infection and rheumatoid arthritis: Faraway, so close! [europepmc]
• Translating IL-6 biology into effective treatments. [europepmc]
• JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. [europepmc]
• Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies. [europepmc]
• Only Hyperuricemia with Crystalluria, but not Asymptomatic Hyperuricemia, Drives Progression of Chronic Kidney Disease. [europepmc]
• JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data. [europepmc]
• EULAR definition of difficult-to-treat rheumatoid arthritis. [europepmc]
• Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. [europepmc]
• The Pretreatment Gut Microbiome Is Associated With Lack of Response to Methotrexate in New-Onset Rheumatoid Arthritis. [europepmc]
• Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. [europepmc]
• Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. [europepmc]
• Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. [europepmc]
• EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. [europepmc]
• Macrophages: The Good, the Bad, and the Gluttony. [europepmc]
• SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-Analysis. [europepmc]
• Management of Rheumatoid Arthritis: An Overview. [europepmc]
• Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies. [europepmc]
• Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial. [europepmc]
• The effect of exercise on cytokines: implications for musculoskeletal health: a narrative review. [europepmc]
• Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. [europepmc]
• Inflammation and Bone Metabolism in Rheumatoid Arthritis: Molecular Mechanisms of Joint Destruction and Pharmacological Treatments. [europepmc]
• Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial. [europepmc]
• Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. [europepmc]
• The development of COVID-19 treatment. [europepmc]
• Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. [europepmc]